UNASSIGNED: This study aims to analyze the antigenicity of the vaccine candidate by examining antibody binding and T-cell activation in individuals infected with SARS-CoV-2 or variants of concern (VOCs), as well as in healthy volunteers who received coronavirus disease 2019 (COVID-19) vaccinations.
UNASSIGNED: Our findings indicate that the vaccine effectively binds antibodies and activates T-cells in individuals who received 2 or 3 doses of BNT162b2 or AZ/ChAdOx-1-S vaccines. Furthermore, the stimulation of T-cells from patients and vaccine recipients with AVX/COVID-12 resulted in their proliferation and secretion of interferon-gamma (IFN-γ) in both CD4+ and CD8+ T-cells.
UNASSIGNED: The AVX/COVID-12 vectored vaccine candidate demonstrates the ability to stimulate robust cellular responses and is recognized by antibodies primed by the spike protein present in SARS-CoV-2 viruses that infected patients, as well as in the mRNA BNT162b2 and AZ/ChAdOx-1-S vaccines. These results support the inclusion of the AVX/COVID-12 vaccine as a booster in vaccination programs aimed at addressing COVID-19 caused by SARS-CoV-2 and its VOCs.
■本研究旨在通过检查感染SARS-CoV-2或关注变种(VOC)的个体的抗体结合和T细胞活化来分析候选疫苗的抗原性,以及接受2019年冠状病毒病(COVID-19)疫苗接种的健康志愿者。
■我们的发现表明,该疫苗有效结合抗体并激活接受2或3剂BNT162b2或AZ/ChAdOx-1-S疫苗的个体的T细胞。此外,用AVX/COVID-12刺激患者和疫苗接受者的T细胞,导致其在CD4+和CD8+T细胞中增殖和分泌干扰素-γ(IFN-γ).
AVX/COVID-12载体疫苗候选物显示出刺激强烈细胞反应的能力,并被感染患者的SARS-CoV-2病毒中存在的刺突蛋白引发的抗体识别,以及BNT162b2mRNA和AZ/ChAdOx-1-S疫苗。这些结果支持将AVX/COVID-12疫苗纳入疫苗接种计划,旨在解决SARS-CoV-2及其挥发性有机化合物引起的COVID-19。